With highly specific antibodies, BAFF can be bound and neutralized. Those antibodies where tested for their effects on the development of atherosclerosis in mice by scientists from CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences and the Medical University of Vienna in collaboration with the University of Cambridge. The results were surprising: instead of reducing atherosclerotic lesion formation in the arteries of the tested mice, the antibody treatment lead to an increased plaque size. The findings were published in Circulation.
"We were able to show that B2 lymphocytes were efficiently depleted upon anti-BAFF antibody treatment," senior author of the study Christoph Binder, CeMM Principal Investigator and Professor for Atherosclerosis Research...
Wake Up To Breaking News!
NY Times, a small niche paper for a small niche people in a really big internet